Cary Claiborne

Cary Claiborne General Information

Biography

Mr. Cary Claiborne serves as Chief Executive Officer and Board of Director at Adial Pharmaceuticals. He served as Chief Operating Officer and Board Member at Adial Pharmaceuticals. Mr. Claiborne previously served as CFO and board member of Indivior PLC, a publicly traded specialty pharmaceutical company developing medicines to treat addiction and serious mental illnesses, from November 2014 until February 2018, when he left Indivior and focused his efforts on Prosperity Capital Management, LLC, a Private Investment and Advisory firm, which he founded in 2001 and where he is currently the CEO. Prior to joining Indivior, Mr. Claiborne served as the CFO of Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, which was later sold to Mallinckrodt. Before joining Sucampo, Mr. Claiborne served as CFO and Corporate Secretary of Osiris Therapeutics, Inc. and oversaw corporate finance during the company's initial public offering. Other previous positions include executive officer or finance roles in a number of companies including, without limitation New Generation Biofuels, Inc. (Nasdaq: NGBF), where he served as CFO and then CEO, Constellation Energy, The Home Depot, MCI, and GE Capital, and GE, where he worked for 15 years. Cary was also a member of the board of directors of MedicAlert Foundation from 2013-2016, where he served as the Chairman of their Audit & Finance Committees. Mr. Claiborne graduated from Rutgers University with a B.A. in Business Administration and from Villanova University with an M.B.A. and was a National Association of Corporate Directors (NACD) Governance Fellow. On December 6, 2021, Adial Pharmaceuticals, Inc. appointed Cary Claiborne as the Company's Chief Operating Officer. On November 2, 2021, Mr. Claiborne was appointed to serve as a Class I member of the Company's Board of Directors (the Board) and will continue to serve as both a director and an executive officer of the Company.